Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN� 2)

This trial is conducted in Africa, Asia, Europe and South and North America. The aim of the trial is to evaluate efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD (thiazolidinedione) in subjects with type 2 diabetes.


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2 - vs. DPP-4 Inhibitor)
Enrollment: 1230
Study Start Date: December 2013
Study Completion Date: October 2015
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)

Arms:
- Experimental: Semaglutide 0.5 mg + sitagliptin placebo
- Experimental: Semaglutide 1.0 mg + sitagliptin placebo
- Active Comparator: Sitagliptin 100 mg + semaglutide placebo 1.0 mg
- Active Comparator: Sitagliptin 100 mg + semaglutide placebo 0.5 mg